Focused Investment in Research and Development
First written in FY2016. 13 of 43 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2027-H1.
- FY2027-H1Increase in R&D Expenses for the Interim PeriodAnnual report
「Group-wide R&D spending for the interim consolidated fiscal period was ¥27,355 million. There was also no material change in the status of R&D activities during the interim consolidated fiscal period.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that interim-period R&D spending increased from ¥23,776 million in the same period of the previous year to ¥27,355 million. - FY2026AdvancedAnnual report
「R&D activities are conducted in the digital content business and the amusement equipment business. As of the end of the consolidated fiscal year, the Company had 3,011 R&D personnel, representing 75.7% of employees. Group-wide R&D investment for the consolidated fiscal year was ¥54,836 million, representing 28.1% of sales.」
R&D personnel increased to 3,011, while R&D investment increased to ¥54,836 million. - FY2026-H1Increase in R&D Expenses for the Interim PeriodAnnual report
「The Group's total R&D expenses for the six-month period ended 30 September amounted to ¥23,776 million.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that interim-period R&D spending increased from ¥22,160 million in the same period of the previous year to ¥23,776 million. - FY2025AdvancedAnnual report
「Group-wide R&D investment for the consolidated fiscal year was ¥49,496 million, representing 29.2% of sales.」
R&D investment increased from ¥43,042 million in the previous fiscal year to ¥49,496 million, while R&D personnel also increased to 2,846, representing 75.6% of employees. - FY2025-H1AdvancedAnnual report
「Group-wide R&D spending for the interim consolidated fiscal period was ¥22,160 million.」
The Company continued its policy of emphasizing R&D, and R&D spending increased from ¥18,932 million in the same period of the previous year to ¥22,160 million. - FY2024AdvancedAnnual report
「Group-wide R&D investment for the consolidated fiscal year was ¥43,042 million, representing 28.2% of sales.」
R&D investment increased from ¥37,719 million in the previous fiscal year to ¥43,042 million, and the proportion of sales rose to 28.2%. - FY2024-Q3Quarterly research and development expenses continue to increaseAnnual report
「Group-wide R&D spending for the cumulative third quarter of the consolidated fiscal year was ¥29,207 million.」
R&D spending increased from ¥27,144 million in the same period of the previous year to ¥29,207 million. The Company stated that there had been no material change in the status of R&D activities. - FY2024-Q2Quarterly research and development expenses continue to increaseAnnual report
「Group-wide R&D spending for the cumulative second quarter of the consolidated fiscal year was ¥18,932 million. There was also no material change in the status of R&D activities during the cumulative second quarter of the consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending increased from ¥18,065 million in the same period of the previous year to ¥18,932 million. - FY2024-Q1Quarterly research and development expenses continue to increaseAnnual report
「The Group's total R&D expenses for the 3-month period ended 30 June amounted to ¥9,256 million. There were also no material changes in the status of R&D activities during the 3-month period ended 30 June.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that quarterly R&D spending increased from ¥7,385 million in the same period of the previous year to ¥9,256 million. - FY2023AdvancedAnnual report
「Group-wide R&D investment for the consolidated fiscal year was ¥37,719 million, representing 30.0% of sales.」
R&D investment increased from ¥29,862 million in the previous fiscal year to ¥37,719 million, while R&D personnel also increased to 2,460. - FY2023-Q3Quarterly research and development expenses continue to increaseAnnual report
「Group-wide R&D spending for the cumulative third quarter of the consolidated fiscal year was ¥27,144 million.」
R&D spending increased from ¥22,842 million in the same period of the previous year to ¥27,144 million. The Company stated that there had been no material change in the status of R&D activities. - FY2023-Q2Quarterly research and development expenses continue to increaseAnnual report
「The Group’s R&D expenditure during the second quarter of the current consolidated fiscal year was ¥18.065 billion. There were no material changes in the status of R&D activities during the second quarter of the current consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending increased from ¥16,161 million in the same period of the previous year to ¥18,065 million. - FY2023-Q1Increase in quarterly R&D expenseAnnual report
「The Group’s R&D expenditure during the first quarter of the current consolidated fiscal year was ¥8.364 billion. There were no material changes in the status of R&D activities during the first quarter of the current consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that quarterly R&D spending increased from ¥7,385 million in the same period of the previous year to ¥8,364 million. - FY2022AdvancedAnnual report
「As of the end of the consolidated fiscal year, the Company had 2,369 R&D personnel, representing 73.9% of employees. Group-wide R&D investment for the consolidated fiscal year was ¥29,862 million, representing 27.1% of sales.」
The Company disclosed 2,369 R&D personnel and R&D investment of ¥29,862 million, representing 27.1% of sales. - FY2022-Q3Quarterly research and development expenses continue to increaseAnnual report
「Group-wide R&D spending for the cumulative third quarter of the consolidated fiscal year was ¥22,842 million.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending increased from ¥18,118 million in the same period of the previous year to ¥22,842 million. - FY2022-Q2Increase in quarterly R&D expenseAnnual report
「Group-wide R&D spending for the cumulative second quarter of the consolidated fiscal year was ¥16,161 million.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending increased from ¥12,432 million in the same period of the previous year to ¥16,161 million. - FY2022-Q1Increase in quarterly R&D expenseAnnual report
「Group-wide R&D spending for the cumulative first quarter of the consolidated fiscal year was ¥7,385 million.」
Quarterly R&D spending increased from ¥6,216 million in the same period of the previous year to ¥7,385 million. The Company stated that there had been no material change in the status of R&D activities. - FY2021Decline in R&D investment and increase in personnelAnnual report
「As of the end of the consolidated fiscal year, the Company had 2,285 R&D personnel, representing 72.5% of employees. Group-wide R&D investment for the consolidated fiscal year was ¥25,375 million, excluding consumption taxes and other taxes, representing 26.6% of sales.」
R&D personnel increased from 2,142 in the previous fiscal year to 2,285, while R&D investment declined from ¥25,843 million to ¥25,375 million. - FY2021-Q3Continued decline in quarterly R&D spendingAnnual report
「The Group’s R&D expenditure during the third quarter of the current consolidated fiscal year was ¥18.118 billion. There were no material changes in the status of R&D activities during the third quarter of the current consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending declined from ¥18,923 million in the same period of the previous year to ¥18,118 million. - FY2021-Q2Continued decline in quarterly R&D spendingAnnual report
「The Group’s R&D expenditure during the second quarter of the current consolidated fiscal year was ¥12.432 billion. There were no material changes in the status of R&D activities during the second quarter of the current consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending declined slightly from ¥12,453 million in the same period of the previous year to ¥12,432 million. - FY2021-Q1Continued decline in quarterly R&D spendingAnnual report
「The Group’s R&D expenditure during the first quarter of the current consolidated fiscal year was ¥6.216 billion. There were no material changes in the status of R&D activities during the first quarter of the current consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending declined from ¥6,368 million in the same period of the previous year to ¥6,216 million. - FY2020Increase in R&D personnel and decline in investmentAnnual report
「As of the end of the consolidated fiscal year, the Company had 2,142 R&D personnel, representing 72% of employees. Group-wide R&D investment for the consolidated fiscal year was ¥25,843 million, excluding consumption taxes and other taxes, representing 31.7% of sales.」
R&D personnel increased from 2,032 in the previous fiscal year to 2,142, while R&D investment declined from ¥27,038 million to ¥25,843 million. The policy of emphasizing R&D itself continued. - FY2020-Q3Continued decline in quarterly R&D spendingAnnual report
「Group-wide R&D spending for the cumulative third quarter of the consolidated fiscal year was ¥18,923 million. There was also no material change in the status of R&D activities during the cumulative third quarter of the consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending declined from ¥21,684 million in the same period of the previous year to ¥18,923 million. - FY2020-Q2Continued decline in quarterly R&D spendingAnnual report
「The Group’s R&D expenditure during the second quarter of the current consolidated fiscal year was ¥12.453 billion. There were no material changes in the status of R&D activities during the second quarter of the current consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that R&D spending declined from ¥14,835 million in the same period of the previous year to ¥12,453 million. - FY2020-Q1Decline in quarterly R&D expensesAnnual report
「The Group’s R&D expenditure during the first quarter of the current consolidated fiscal year was ¥6.368 billion. There were no material changes in the status of R&D activities during the first quarter of the current consolidated fiscal year.」
While stating that there had been no material change in its policy of emphasizing R&D, the Company reported that quarterly R&D spending declined from ¥7,259 million in the same quarter of the previous year to ¥6,368 million. - FY2019Decline in R&D investmentAnnual report
「As of the end of the consolidated fiscal year, the Company had 2,032 R&D personnel, representing 72% of employees. Group-wide R&D investment for the consolidated fiscal year was ¥27,038 million, excluding consumption taxes and other taxes, representing 27.0% of sales.」
The policy of emphasizing R&D continued, but R&D personnel declined from 2,141 in the previous fiscal year to 2,032, while investment declined from ¥28,990 million to ¥27,038 million. - FY2019-Q3RestatedAnnual report
「The Group’s R&D expenditure during the third quarter of the current consolidated fiscal year was ¥20.330 billion. There were no material changes in the status of R&D activities during the third quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed cumulative R&D spending of ¥20,330 million for the third quarter. - FY2019-Q2RestatedAnnual report
「The Group’s R&D expenditure during the second quarter of the current consolidated fiscal year was ¥14.152 billion. There were no material changes in the status of R&D activities during the second quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed cumulative R&D spending of ¥14,152 million for the second quarter. - FY2019-Q1RestatedAnnual report
「The Group’s R&D expenditure during the first quarter of the current consolidated fiscal year was ¥7.259 billion. There were no material changes in the status of R&D activities during the first quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed R&D spending of ¥7,259 million for the first quarter. - FY2018AdvancedAnnual report
「As of the end of the consolidated fiscal year, the Company had 2,141 R&D personnel, representing 73% of employees. Group-wide R&D investment for the consolidated fiscal year was ¥28,990 million, excluding consumption taxes and other taxes, representing 30.7% of sales.」
The Company disclosed 2,141 R&D personnel, representing 73% of employees, and R&D investment of ¥28,990 million, representing 30.7% of sales. Investment increased from ¥27,720 million in the previous fiscal year. - FY2018-Q3RestatedAnnual report
「The Group’s R&D expenditure during the third quarter of the current consolidated fiscal year was ¥21.684 billion. There were no material changes in the status of R&D activities during the third quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed cumulative R&D spending of ¥21,684 million for the third quarter. - FY2018-Q2RestatedAnnual report
「The Group’s R&D expenditure during the second quarter of the current consolidated fiscal year was ¥14.835 billion. There were no material changes in the status of R&D activities during the second quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed R&D spending of ¥14,835 million for the cumulative second quarter. - FY2018-Q1RestatedAnnual report
「The Group’s R&D expenditure during the first quarter of the current consolidated fiscal year was ¥7.320 billion. There were no material changes in the status of R&D activities during the first quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed R&D spending of ¥7,320 million for the first quarter. - FY2017RestatedAnnual report
「The Company recognizes that developing new products to anticipate changes in the times and in values and meet market needs is its core business, and therefore places a strong emphasis on research and development.」
The Company continued its policy of emphasizing R&D and disclosed 1,994 R&D personnel, representing 71% of employees, and R&D investment of ¥27,720 million, representing 31.8% of sales. - FY2017-Q3RestatedAnnual report
「The Group’s R&D expenditure during the third quarter of the current consolidated fiscal year was ¥20.210 billion. There were no material changes in the status of R&D activities during the third quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed R&D spending of ¥20,210 million for the cumulative third quarter. - FY2017-Q2AdvancedAnnual report
「Against this backdrop, our group advanced the expansion of its development operations, including the full-scale launch in April this year of the Research and Development Building No. 2, a new development centre equipped with state-of-the-art facilities comparable to those of a Hollywood studio in the United States, including a motion-capture studio.」
Regarding R&D activities, the Company brought its second R&D building, equipped with state-of-the-art facilities, fully online in April. R&D expenses totaled ¥13,615 million for the cumulative second quarter, and the Company stated that there had been no material change. - FY2017-Q1RestatedAnnual report
「The Group’s R&D expenditure during the first quarter of the current consolidated fiscal year was ¥6.846 billion. There were no material changes in the status of R&D activities during the first quarter of the current consolidated fiscal year.」
The Company stated that there had been no material change in its policy of emphasizing R&D and disclosed R&D spending of ¥6,846 million for the quarter. - FY2016First statedAnnual report
「The Company recognizes that developing new products to anticipate changes in the times and in values and meet market needs is its core business, and therefore places a strong emphasis on research and development.」
The Company disclosed 2,052 R&D personnel, representing 72% of employees, and R&D investment of ¥27,255 million, representing 35.4% of sales.